Abstract
The use of recombinant activated factor VII (rFVIIa) is gaining popularity in coagulopathic trauma patients. Its utility in patients on warfarin with traumatic intracranial hemorrhage (tICH) is unclear. The objective of this study was to compare outcomes in emergency department patients with pre-injury warfarin use and tICH who did and did not receive rFVIIa for reversal of their coagulopathy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
